Breast Cancer Clinical Trial
Official title:
Effect of Sukshma Vyayama Joint Loosening Yoga on Aromatase Inhibitor-Induced Arthralgia in Post-Menopausal Breast Cancer Survivors: A Feasibility Study Conducted on Facebook
The purpose of this study is to investigate the efficacy of sukshma vyayama joint loosening yoga in improving aromatase inhibitor-induced arthralgia in post-menopausal breast cancer survivors and secondarily, to evaluate the feasibility of delivering the intervention on Facebook.
Cancer survival rates are improving in the United States but this increased survivorship is
offset by persistent treatment related symptoms, particularly for post-menopausal breast
cancer survivors treated with aromatase inhibitor (AI) hormonal therapy. AI therapy is well
known to cause arthralgia that can compromise a woman's quality of life. National
Comprehensive Cancer Center Network (NCCCN) guidelines for breast cancer treatment recommend
that post-menopausal women with estrogen receptor-positive tumors receive aromatase
inhibitors, e.g., anastrozole (Arimidex), letrozole (Femara) or exemestane (Aromasin) as a
key part of treatment to lower the risk of breast cancer recurrence, breast cancer in the
opposite breast, and death from breast cancer. Estrogen receptor-positive breast cancer
represents almost 50% of all newly diagnosed cases of breast cancer. Currently, AIs are
prescribed for five to ten years. The length of this treatment, coupled with difficult
arthritic side effects can make it difficult for patients to complete therapy. Arthralgia
occurs in up to 50% of breast cancer survivors treated with AIs and is the most common reason
for poor AI adherence. Up to 50% of patients do not take AIs as prescribed and up to 20% will
become non-compliant with treatment within the first year due to pain and discomfort. To get
the most benefit out of hormone therapy, however, patients must take the full course of
treatment. Both non-adherence and early discontinuation of AIs have been shown to be
independent predictors of mortality. Women who complete the full course have better survival
than those who do not. Given the efficacy of AIs in preventing breast cancer recurrence, and
the proportion of women who discontinue these drugs because of adverse events, interventions
to improve adverse effects are important.
This study investigated the efficacy of sukshma vyayama joint loosening yoga in reducing and
improving aromatase inhibitor-induced joint pain and achiness in post-menopausal breast
cancer patients, and evaluated the feasibility of delivering the intervention on Facebook.
Hypothesis: Given global disparities in healthcare, being able to safely deliver
evidence-based yoga interventions via the internet is important.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |